Patents by Inventor Yu-Wai CHEN

Yu-Wai CHEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Peptides for specific inhibition of Jag 1-Notch 1 pathway
    Patent number: 11117932
    Abstract: Aberrant cross talk between Notch ligand (e.g. Jag1) and Notch receptor (e.g. Notch1) has been implicated in tumorigenesis in the colon. Inhibition of Notch pathway is therefore an attractive approach for treating diseases with upregulated Jag1 e.g. colorectal cancer (CRC). Pan-notch inhibitors like gamma secretase inhibitors (GSIs) have been developed to inhibit Notch and its downstream events. However, severe gastrointestinal toxicity profiles impede the clinical development of GSIs. The present invention develops novel oligopeptides that specifically inhibit Jag1-Notch1 pathway without interfering DLL1-Notch1 or DLL4-Notch1, which demonstrates a clear advantage over pan-notch inhibitors.
    Type: Grant
    Filed: July 19, 2019
    Date of Patent: September 14, 2021
    Assignees: The Hong Kong Polytechnic University, The Royal Institution for the Advancement of Learning/McGill University
    Inventors: Xuezhen Zhu, Yu-Wai Chen, Tak Hang William Chan, Ming Cheung Chow
  • PEPTIDES FOR SPECIFIC INHIBITION OF JAG1-NOTCH1 PATHWAY
    Publication number: 20210246168
    Abstract: Aberrant cross talk between Notch ligand (e.g. Jag1) and Notch receptor (e.g. Notch1) has been implicated in tumorigenesis in the colon. Inhibition of Notch pathway is therefore an attractive approach for treating diseases with upregulated Jag1 e.g. colorectal cancer (CRC). Pan-notch inhibitors like gamma secretase inhibitors (GSIs) have been developed to inhibit Notch and its downstream events. However, severe gastrointestinal toxicity profiles impede the clinical development of GSIs. The present invention develops novel oligopeptides that specifically inhibit Jag1-Notch1 pathway without interfering DLL1-Notch1 or DLL4-Notch1, which demonstrates a clear advantage over pan-notch inhibitors.
    Type: Application
    Filed: July 19, 2019
    Publication date: August 12, 2021
    Inventors: Xuezhen ZHU, Yu-Wai CHEN, Tak Hang William CHAN, Ming Cheung CHOW